Vaxcyte (PCVX) Equity Average (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Equity Average data on file, last reported at $2.8 billion in Q1 2026.

• Equity Average for Q1 2026 came in at $2.8 billion, down 12.67% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.8 billion (down 12.67% YoY), and the FY2025 annual result was $3.0 billion, up 31.79% from the prior year.
• Equity Average rose to $2.8 billion in Q1 2026 per PCVX's latest filing, from $2.8 billion in the prior quarter.
• Over five years, Equity Average peaked at $3.4 billion in Q4 2024 and troughed at $321.8 million in Q1 2022.
• A 5-year average of $1.8 billion and a median of $1.6 billion in 2024 frame the typical range for Equity Average.
• The sharpest annual moves came in 2023 and 2025: Equity Average surged 290.75% in 2023, then declined 17.03% in 2025.
• A 5-year view of Equity Average shows it stood at $656.5 million in 2022, then soared by 101.32% to $1.3 billion in 2023, then surged by 154.37% to $3.4 billion in 2024, then decreased by 17.03% to $2.8 billion in 2025, then rose by 1.85% to $2.8 billion in 2026.
• Business Quant data shows PCVX's Equity Average at $2.8 billion in Q1 2026, $2.8 billion in Q4 2025, and $3.0 billion in Q3 2025.